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1. Introduction
Locally advanced breast cancer (LABC) occurs at presentation in approximately 20-25% of
breast cancer patients worldwide, but significantly less in countries with implemented
screening programs. LABC refers to large operable (stage IIB, IIIA) or inoperable (stage IIIB,
IIIC) tumors, including inflammatory breast cancer. Patients with ipsilateral supraclavicular
lymph node involvement previously considered as having metastatic disease are now also
included in the category of LABC (stage IIIC). Treatment of LABC has evolved within recent
decades. For a long time, mastectomy remained the mainstay of treatment in this group of
patients, but long-term local control was disappointingly low, with approximately 50% local
recurrences (LR) and only 2% 5-year overall survival (OS). Implementation of postoperative
radiotherapy increased local control and survival, but long-term outcomes remained unsat‐
isfactory (35-55% LR and 25-45% five-year OS). Incorporating systemic therapy (be it chemo‐
therapy, hormonal therapy or both) as an adjunct to surgery and/or radiotherapy further
improved results. Currently, a combination of systemic therapy with locoregional treatment
(surgery and/or radiotherapy) constitutes the standard of care in LABC patients since im‐
proving locoregional control is associated with better survival. In patients with stage III
breast cancer treated with induction chemotherapy followed by surgery, radiotherapy or a
combination thereof, the risk of loco regional recurrence is in the range of 20%. The use of
induction systemic therapy results in tumor downstaging, and in selected LABC patients
even allows for breast conserving surgery (BCS). However, the safety and efficacy of this ap‐
proach in LABC have not been verified in randomized studies. Even though locoregional
management is an important component of multimodality treatment in patients with LABC,
the pattern of local management and factors influencing local treatment strategy in this
group are not well recognized (Sinacki et al., 2011). Neoadjuvant therapy is recommended
not only for locally advanced and inflammatory breast cancer but also as an option for pri‐
mary operable disease without compromising long-term outcome (Untch et al., 2011).
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2. Neoadjuvant systemic therapy
2.1. Neoadjuvant chemotherapy
Patients presenting with locally advanced primary breast cancer (LAPC) are a heterogene‐
ous group with variable outcomes with regard to local recurrence rates and survival. There
is no standard or international agreement on the definition of this type of breast cancer, but
one commonly used clinical staging includes patients with large primary tumours greater
than 5 cm (T3) or with fixed skin or chest involvement (T4), and/or fixed axillary (N2) or ip‐
silateral internal mammary lymph node involvement (Mathew et al., 2008). According to
TNM staging system proposed by the American Joint Committee on Cancer (AJCC), all of
stage III disease is therefore considered locally advanced, as is a subset of stage IIB (T3N0).
In addition, inflammatory breast cancer (T4d), with its distinct clinical presentation and
worse prognosis, is included within the scope of locally advanced disease. Although the
TNM system is not as widely used in some countries, it is generally accepted that locally ad‐
vanced breast cancers represent those cancers that are difficult to resect with primary sur‐
gery either because of their size or extension to chest wall or skin or involvement of regional
axillary lymph nodes. Compared to patients with operable primary breast cancer, patients
with LAPC are at significantly higher risk of local recurrence and distant metastases and
have a worse overall survival; UK figures show that patients with stage II disease have a 10-
year survival rate of just under 60%, whereas this is approximately 30% for patients with
stage III disease (Mathew et al., 2008).
With the widespread use of breast cancer screening, breast cancers are increasingly being di‐
agnosed at an earlier stage. Because of this, patients with locally advanced breast cancer are
less commonly seen than before. Nevertheless, there remains a group of patients who either
because they do not seek advice earlier or because the tumour is more aggressive, present
with locally advanced disease. Data from the American National Cancer Institute’s Surveil‐
lance, Epidemiology, and End Results (SEER) program show that 7% of all breast cancer pa‐
tients have stage III disease at diagnosis, although this percentage is less than 5% in the
screening population. Despite this, patients with LAPC still present a significant clinical
problem and exemplify a subgroup of patients where a multidisciplinary approach is partic‐
ularly important to outcome.
Initially, an aggressive single modality, local therapy approach, was commonly advocated
for the treatment of patients with LAPC, either in the form of radical surgery or radiothera‐
py. This often provided temporary local control, although on follow-up of these patients, the
morbidity and recurrence rates were high and survival poor. Multimodal approach is now
an established option in most patients with LAPC, especially oestrogen receptor (ER) nega‐
tive tumours or aggressive ER positive tumours (e.g. some inflammatory cancers). This in‐
cludes the combination of surgery and radiotherapy for local control and systemic therapy,
usually chemotherapy +/ - hormone therapy. For others, such as those with strongly hor‐
mone receptor positive tumours, local treatments (i.e. surgery +/- radiotherapy) plus endo‐
crine therapy or even primary endocrine therapy may be appropriate options. This may for
example be the case in many elderly patients, some of who are medically unfit for surgery.
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A large number of studies have assessed the use of neoadjuvant chemotherapy in operable
primary breast cancer. Although the results in operable breast cancers suggest that the
breast conserving rates can be increased, survival is no different when compared to post-op‐
erative adjuvant chemotherapy. However, patients with LAPC often have inoperable dis‐
ease at diagnosis and the main goal of neoadjuvant treatment is to achieve resectability,
either in the form of standard mastectomy or breast-conserving surgery. Furthermore, the
clinical and histological response to neoadjuvant chemotherapy has been shown to be im‐
portant predictors of recurrence and survival in studies of operable breast cancer. Neoadju‐
vant chemotherapy (NACT) in operable invasive breast cancer (OIBC) has been shown to
increase breast conservation surgery (BCS) (Cebrecos et al., 2010). However, chemoresistant
and multi focal tumours still require a mastectomy. As a consequence, today global manage‐
ment of these patients may include a breast reconstruction (Monrigal et al., 2011)
2.2. Definition and impact of pathologic complete response on prognosis after
neoadjuvant therapy
Neoadjuvant chemotherapy represents an option for patients with early breast cancer when
an indication for chemotherapy is given. Phathologic complete response (pCR) has predict‐
ed long-term outcome in several neoadjuvant studies and is therefore a potential surrogate
marker for survival. However, selected trials comparing different neoadjuvant regimens
have failed to demonstrate an association between pCR rate and improved outcome (von
Minckwitz et al., 2012)
Methodologic limitations are likely to be the reason for this unexpected discrepancy. First,
no standardized definition for pCR exists. Some trials have applied the pCR definition to the
breast tumor only, whereas others have included the axillary nodes. Furthermore, some
studies have included the presence of focal invasive cancer or noninvasive cancer residuals
in their pCR definition whereas others have defined pCR as the complete eradication of all
invasive and noninvasive cancer. Second, incidence and prognostic impact of pCR vary
among breast cancer-intrinsic subtypes. For example, although patients with luminal A
breast cancer show a low pCR rate, their overall prognosis is favorable, whereas patients
with triple-negative (TN) breasi cancer show a high pCR rate but have an unfavorable out‐
come (von Minckwitz et al., 2012). Including all intrinsic subtypes might therefore attenuate
the prognostic information of pCR.
Pathologic complete response (pCR) defined as no invasive and no in situ residuals in breast
and nodes can best discriminate between patients with favorable and unfavorable outcomes.
Patients with noninvasive or focal-invasive residues or involved lymph nodes should not be
considered as having achieved pCR. pCR is a suitable surrogate end point for patients with
luminal B/HER2-negative, HER2-positive (nonluminal), and triple-negative disease but not
for those with luminal B/HER2-positive or luminal A tumors (von Minckwitz et al., 2012).
This is, to the best of our knowledge, the first individual patient- based pooled analysis ana‐
lyzing different pCR definitions for their prognostic impact on survival of patients with
breast cancer treated with neoadjuvant anthracycline-taxane-based chemotherapy. The large
patient collective included sufficient subpopulations with small residual disease volume (eg,
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noninvasive residuals only, focal-invasive disease < 5 mm, or no invasive tumor in the
breast but involved lymph nodes). Over the last decades, these subpopulations have fre‐
quently been considered to have achieved pCR. However, (von Minckwitz et al., 2012) show
that these subpopulations have an increased risk of relapse and sometimes of death as well
compared with the group of patients with stage ypT0 ypN0 breast cancer. pCR restricted to
this stage showed the lowest adjusted HR for DFS and OS compared with the other defini‐
tions (Schott et al., 2012; von Minckwitz et al., 2012) further demonsfrate that in subgroups
considered to have slowly proliferating tumors, pCR is not associated with prognosis,
whereas in subgroups with highly proliferating tumors, pCR can discriminate between pa‐
tients with good and poor prognosis accurately. The recently proposed clinicopathologic
definition of the St Gallen panel nicely recognizes these subgroups. In fact, prognostic im‐
pact of pCR is highest in HER2-positive (nonluminal) and TN tumors, where patients ach‐
ieving pCR show a prognosis comparable to that of patients with luminal A tumors.
Surprisingly, pCR was not prognostic in the luminal B/HER2positive subgroup irrespective
of trastuzumab treatment. In this subgroup, pCR rates were low, despite concomitant anti-
HER2 therapies, but similar outcomes were observed in the adjuvant trastuzumab studies.
In the research setting, Schott and Hayes (2012) recommend that neoadjuvant trials that are
testing classic cytotoxic drugs with pCR as the primary end point should enroll only pa‐
tients with ER-negative or highly proliferative tumors, given that these are the patients for
whom pCR is shown to have prognostic value. In these instances, every body adoption of a
uniform definition of pCR, which is substantially clarified by the data from von Minckwitz
et al (2012). Uniform definitions for concepts such as pathologic complete response (pCP)
can provide a framework for reporting clinical trial results in a coherent manner.
2.3. Neoadjuvant endocrine therapy
Duration of neoadjuvant hormonal treatment for breast cancer in most studies was 3-6
months. The few studies that investigated prolonged treatment with neoadjuvant endocrine
therapy suggest that a further reduction in tumour size can be achieved and that even sur‐
gery can be withheld for elderly women on continuing hormonal treatment. However, the
optimum duration of neoadjuvant endocrine therapy has to be established. For many years,
primary systemic (neoadjuvant) therapy has been given before local treatment for women
with locally advanced breast cancer in an effort to make such disease operable. Chemothera‐
py has been the mainstay of this approach, but more recently neoadjuvant endocrine thera‐
py has emerged as an attractive alternative in post-menopausal women with large hormone
receptor positive breast cancers. A number of randomized trials (like P024, IMPACT, PRO‐
ACT) have compared various aromatase inhibitors directly with tamoxifen. An important
endpoint in each of these studies has been the rate at which breast conservation has been
achieved. The presence of steroid hormone receptors (ER and/or PR) are target for endocrine
therapy. Preoperative chemotherapy may be less effective in postmenopausal patients with
ER-positive and/or PR-positive tumors at least with respect to doxorubicin-containing or
taxane-containing regimens. Pathological complete response (pCR) rates after chemotherapy
were significantly higher among patients with tumors that were both ER-negative and PR-
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negative compared with patients whose tumors had any (even low) expression of steroid
hormone receptors (Colleoni et al. 2004, 2008). In the ECTO I trial, pCR after neoadjuvant
chemotherapy was observed in 42% of women with ER22 negative tumors, compared with
12% in the ER-positive group (Gianni et al. 2009). In the NSABP B-27 study, ER-negative tu‐
mors had higher rates of pCR than ER-positive tumors when treated with neoadjuvant AC,
as well as when treated with AC followed by docetaxel (Bear et al., 2006). Before our trial
there were few, if any, direct comparisons of primary neoadjuvant endocrine therapy with
primary neoadjuvant chemotherapy in patients with hormone-responsive breast cancer.
This was an open-label, randomized phase 2 trial of once-daily endocrine therapy (exemes‐
tane or anastrozole) or chemotherapy (doxorubicin and paclitaxel, every 3 week for 4 cycles)
in postmenopausal women with primary ER-positive breast cancer. A total of 239 patients
with ER-positive and/or PgR-positive breast cancer (T2N1-2, T3N0-1, T4N0M0) were ran‐
domly assigned to receive neoadjuvant endocrine therapy (ET) [anastrazole 1 mg/day or ex‐
emestane 25 mg/day for 3 months, 121 patients] or chemotherapy (CT) [doxorubicin 60
mg/m2 with paclitaxel 200 mg/m2, four 3-week cycles, 118 patients]. All patients were con‐
sidered to be ineligible for breast-conserving surgery (BCS) at enrollment. After BCS all pa‐
tients received radiotherapy (50 Gy in 25 fractions). The median follow-up time was 5.6
years.
The primary efficacy end point was already reported (Semiglazov et al., 2007). Overall re‐
sponse (OR=CR+PR) was similar in the endocrine therapy group (65.5%) compared with
chemotherapy group (63.6%; p>0.5). Interim analysis of this trial showed similar objective
response in patients who were receiving exemestane and in patients who were receiving
anastrazole. It allowed us to review and to analyze dates on all patients who were receiving
aromatase inhibitors in the endocrine therapy group. There was a trend toward higher over‐
all rates of OR and breast-conserving surgery among patients with tumors expressing high
levels of ER (Allred score ≥6) in the endocrine therapy compared with the chemotherapy
group (43% vs 24%, p=0.054).
After completing neoadjuvant treatment, 31 patients (13%) did not undergo surgical resec‐
tion: 12.3% of patients who were receiving endocrine therapy and 13.5% of patients who
were receiving chemotherapy. Twenty-two patients did not receive surgery because of dis‐
ease progression. These patients were switched to the other study therapy: patients initially
treated with endocrine therapy received chemotherapy, and patients treated with chemo‐
therapy received endocrine therapy. Progressive disease was observed in 9% of patients
who were receiving endocrine therapy and 9% of patients who were receiving chemothera‐
py (P>0.5). Stable disease was seen in 21% of patients who were receiving endocrine treat‐
ment and 26% of patients who were receiving chemotherapy.
Analysis of BCS rates according to pretreatment characteristics showed a non-significant
trend towards increased BCS in patients with clinical stage T2, ER+/PgR+, 70 years and older
(p=0.054- 0.088) receiving neoadjuvant endocrine therapy.
The rate of BCS was particularly marked in patients receiving endocrine therapy, who ach‐
ieved a clinical response. There was no significant difference between endocrine therapy
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(ET) and chemotherapy (CT) relative to the incidence of locoregional recurrences and dis‐
tant metastases (8.2% and 7.6%, p=0.99; 14.8% and 15.2%, p=0.83, respectively). There was no
significant difference in DFS through 5 years of follow up between the 121 patients who re‐
ceived neoadjuvant endocrine therapy and 118 women who received chemotherapy: 71.0%
and 67.7% (p>0.5). After a median follow up of 5.6 years 35 events had been reported in the
endocrine group (24 in 66 patients who underwent mastectomy and 11 in 40 patients who
underwent BCS). 5-year DFS was 63.6% after mastectomy and 72.5% after BCS (p=0.076).
The incidence of commonly reported adverse events was higher in patients receiving che‐
motherapy. No serious adverse events were reported in patients receiving endocrine thera‐
py. Six patients receiving chemotherapy experienced febrile neutropenia leading to
treatment interruption. No deaths occurred during the preoperative therapy. Our trial has
shown that preoperartive endocrine therapy with aromatase inhibitors offers the same rate
of overall objective response, breast-conserving surgery, 5-years DFS as chemotherapy in
postmenopausal patients with ER-positive tumors. The frequency of adverse events was
higher among patients who were receiving chemotherapy. Endocrine treatment was well
tolerated. Preoperative endocrine therapy with aromatase inhibitors is a reasonable alterna‐
tive to preoperative chemotherapy for postmenopausal women with ER35 positive disease
in clinical situation in which the low toxicity of the regimen is considered an advantage. Ac‐
cording St.Gallen recommendation (Goldhirsch et al., 2009) neoadjuvant endocrine therapy
without chemotherapy was considered reasonable for postmenopausal patients with strong‐
ly receptor-positive disease. If used, such treatment should be considered for a duration of
5-8 months or until maximum tumour response.
2.4. Neoadjuvant therapy in HER2+ breast cancer
Amplification or overexpression, or both, of human epidermal growth factor receptor-2
(HER2, also known as ERBB2), a transmembrane receptor tyrosine kinase, is present in
around 22% of early breast cancers, 35% of locally advanced and metastatic tumours, and
40% of inflammatory breast cancers, and is associated with aggressive disease and poor
prognosis (Ross et al., 2009). Patients with HER2-positive locally advanced or inflammatory
breast cancer are therefore in particular need of effective treatment. Trastuzumab (Hercep‐
tin, Roche, Basel, Switzerland), a recombinant humanized monoclonal antibody that targets
HER2, has efficacy as monotherapy (Baselga et al., 2005) and improves results of chemother‐
apy in patients with HER2-positive metastatic (Slamon et al., 2001; Marty et al., 2005) and
early operable breast cancer (Smith et al., 2007; Romond et al., 2005; Slamon et al., 2005). It is
widely approved for use as monotherapy and in combination with chemotherapy or hor‐
mone therapy in these patients, but not specifically in those with locally advanced or inflam‐
matory breast cancer. In a pilot study, anthracycline and paclitaxel were successfully
combined with trastuzumab in patients with metastastic disease (Bianchi et al., 2003). To re‐
duce the risk of cardiac toxic effects, only three cycles of doxorubicin were given in the pilot
study, which corresponds to a cumulative dose of 180 mg per m2 of body surface area
(Gianni et al., 2009). No patient developed symptomatic cardiac dysfunction, although four
patients (of 16) had reversible asymptomatic decreases in left ventricular ejection fraction to
50% or lower.
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The neoadjuvant Herceptin (NOAH) study was designed to assess efficacy of neoadjuvant
chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant
chemotherapy alone in patients with HER2-positive locally advanced or inflammatory
breast cancer. The NOAH study randomized 228 patients with centrally confirmed HER2+
locally advanced breast cancer to a chemotherapy regimen consisting of 3 cycles of doxoru‐
bicin plus paclitaxel (AT); 4 cycles of paclitaxel (T); and 3 cycles of cyclophosphamide, me‐
thotrexate, and fluorouracil (CMF), with and without trastuzumab. The addition of
trastuzumab significantly improved overall response rate (81% vs 73%, P =0. 18) and pCR
rates (43% vs 23%, P =0,002) (Gianni et al., 2010).
The primary objective was to compare event-free survival, which was defined as time from
randomization to disease recurrence or progression (local, regional, distant, or contralateral)
or death from any cause, in patients with HER2-positive disease treated with and without
trastuzumab.
Trastuzumab significantly improved event-free survival in patients with HER2-positive
breast cancer (3-year event-free survival 71% [95% CI 61-78; n=36 events] with trastuzumab,
vs 56% [46-65; n-51 events] without; hazard ratio 0.59 [95% CI 0-38-0-90]; p-0.013). Trastuzu‐
mab was well tolerated and, despite concurrent administration with doxorubicin, only two
patients (2%) developed symptomatic cardiac failure. Both responded to cardiac drugs. The
results of the NOAH study have shown that in patients with HER2-positive locally ad‐
vanced or inflammatory breast cancer, addition of 1 year of trastuzumab (starting as neoad‐
juvant and continuing as adjuvant therapy) to neoadjuvant chemotherapy improved overall
response rates, almost doubled rates of pathological complete response, and reduced risk of
relapse, progression, or death compared with patients who did not receive trastuzumab. In‐
vestigators recorded a benefit of trastuzumab in all 1 subgroups tested,including women
with inflammatory disease (27% of HER2- positive patients) who benefited substantially
from trastuzumab (Baselga et al., 2005; Semiglazov et al., 2011)
The results of the NOAH study consolidate those of other studies of trastuzumab in the neo‐
adjuvant setting. In these mainly non-randomised studies, pathological complete response
rates (variously defined) ranged from 17% to 73%, and were better than they were in histori‐
cal' or concurrent HER2-negative controls (Gluck et al., 2008; Untch et al., 2008). One rando‐
mised trial in patients with operable non-inflammatory disease was stopped early when the
pathological complete response rate in the trastuzumab group was more than twice as high
as that of the control group (65% vs 26%) (Buzdar et al., 2005). Patient numbers in this study
were small, but preliminary results from another randomized study also show a doubling in
pathological complete response rate in the trastuzumab group. These response rates to pri‐
mary systemic therapy are a surrogate for relapse-free and overall survival in patients who
were unselected for HER2 status.
Despite concurrent use of doxorubicin, paclitaxel, and trastuzumab in the NOAH trial, inci‐
dence of symptomatic cardiac failure was low (<2%) and less than was expected (2.8- 4.1%)
on the basis of adjuvant trials in which trastuzumab was given concurrently with paclitaxel
after completion of doxorubicin and when trastuzumab was given as monotherapy after
completion of a range of cytotoxic regimens (2%). These findings support the accumulating
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evidence that trastuzumab can be given concurrently with anthracyclines with a low fre‐
quency of symptomatic cardiac dysfunction, provided that low cumulative doses or less car‐
diotoxic anthracyclines are used, and careful cardiac monitoring is done.
The addition of trastuzumab to neoadjuvant sequential anthracycline-taxane chemotherapy
(with and without capecitabine) was also investigated in the phase III GeparQuattro study,
and led to a doubling of pCR rates (31.8% vs 15.4%, P <0.001) (Von Minckwitz et al., 2008).
With the emergence of lapatinib (Tykerb), a dual tyrosine kinase inhibitor against HER1 and
HER2, the CALGB is conducting a randomized phase III trial to evaluate paclitaxel with
trastuzumab or lapatinib, or both in the preoperative setting. Several other trials are ongoing
to evaluate these 2 drugs in the neoadjuvant setting, including Neo-ALTTO (Neoadjuvant
Lapatinib and/or Trastuzumab Treatment Optimization) in phase III and CHERLOB in
phase II.
Trastuzumab (H) in combination with chemotherapy improves outcomes in patients with
HER2-positive breast cancer and is integral to the standards of care for these patients. How‐
ever, in some patients disease progression still occurs. Pertuzumab (P) and trastuzumab (H)
target different epitopes of HER2, and their use in combination has demonstrated improve‐
ment in response rates. NEOSPHERE study (Gianni et al., 2011) assessed the efficacy and
safety of pertuzumab added to trastuzumab-based neoadjuvant chemotherapy in women
with HER2-positive operable, locally advanced/inflammatory breast cancer who had not re‐
ceived prior cancer therapy.
Patients (n = 417) with HER2-positive (IHC3+ or IHC2+ and FISH/CISH+) breast cancer were
randomized 1:1:1:1 to receive 4 neoadjuvant cycles of docetaxel (T) plus H, THP, HP or TP.
Pertuzumab (P) was given at a loading dose of 840 mg and 420 mg maintenance, trastuzu‐
mab (H) at a loading dose of 8mg/kg and 6 mg/kg maintenance, and docetaxel (T) at 75
mg/m2 with escalation to 100 mg/m2 if tolerated in a 3weekly schedule. The primary end‐
point was pCR in the breast.
About 40% of patients had locally advanced/inflammatory breast cancer and approximately
50% were ER/PR negative. THP combination (docetaxel + trastuzumab + pertuzumab) sig‐
nificantly improved the pCR rate compared with TH (docetaxel + trastuzumab) alone: 45.8%
(95% CI 36.1-55.7) vs 29.0% (95% CI 20.6-38.5), P = 0.0141. Patients receiving THP (docetaxel
+ trastuzumab + pertuzumab) had the highest pCR rate regardless of ER/PR status, although
the greatest treatment benefit in all 4 arms was observed in ER/PR-neg patients. The chemo‐
therapy-free HP (trastuzumab+pertuzumab) arm achieved a pCR rate of 16.8%. THP (doce‐
taxel + trastuzumab + pertuzumab) had a similar safety profile to TH. The incidence of AEs
was lowest in the HP (trastuzumab+pertuzumab) arm.
Thus, the addition of pertuzumab to trastuzumab-based neoadjuvant chemotherapy result‐
ed in a significant improvement of the pCR rate with no new safety signals of concern. Per‐
tuzumab and trastuzumab have complementary mechanisms of action as pertuzumab
inhibits HER2:HER3 heterodimerisation, thereby providing a potential mechanism to over‐
come tumour escape. These results support the rationale for a planned Phase III, double-
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blind, placebo-controlled trial evaluating pertuzumab added to standard trastuzumab-based
therapy it women with HER2- positive breast cancer.
Dual HER2 inhibition is being examined in neoadjuvant and adjuvant settings. The Neo‐
ALTTO (Neoadjuvant Lapatimib and/or Trastuzumab Treatment Optimisation) study
showed that the addition of lapatinib plus trastuzumab to neoadjuvant chemotherapy re‐
sulted in a higher pathologic complete response rate compared with the addition of trastu‐
zumab or lapatimib monotherapy (51.3% v 29.5% v 24.7%, respectively; P<.01). Also
objective (clinical) response rates at 6 weeks with anti-HER2 therapy alone were 67.1%,
30.2%, and 52.6%, respectively; those at surgery after 18 weeks of neoadjuvant anti-HER2
therapy plus chemotherapy were 80.3%, 70.5%, and 74.0%, respectively, suggesting that the
combination is beneficial in the neoadjuvant setting (Baselga et al., 2012; Blackwell et al
2010-2012).
Despite the dramatic improvement in the outcome of HER2+ breast cancers since the wide‐
spread use of HER2-directed therapies, such as trastuzumab, patients continue to develop
recurrences and disease progression. The mechanisms of intrinsic and acquired resistance to
trastuzumab are likely multifactorial and are being exploited by the use of novel targeted
agents in clinical development. The phosphoinositide-3-kinase (PI3K) pathway plays a key
role in resistance to trastuzumab through increased signaling through upstream growth fac‐
tor receptors, PTEN mutations, and other mechanisms, and therefore, is an excellent target
for drug development in patients with trastuzumab-resistant, HER2+ breast cancers. Availa‐
ble clinical trials demonstrate encouraging activity of mTOR inhibitors in combination with
trastuzumab monotherapy or trastuzumab-based chemotherapy in patients with HER2+
metastatic breast cancer pretreated with trastuzumab with or without lapatinib. The results
of early-stage clinical trials are currently being confirmed in 2 large phase III trials (Brach‐
man et al, 2009; Vazguez-Martin et al, 2009). Other agents, targeting the PI3K pathway, are
in early clinical development for HER2+ breast cancers.
2.5. Triple-negative breast cancer
Triple-negative (ER-negative, PgR-negative, and HER2 receptor-negative) breast cancers
(TNBC) account for approximately 15% of all breast cancers and, though in and of itself it is
a heterogeneous group, it often exhibits an aggressive phenotype with a generally poor
prognosis. Unlike HER2+ or hormone receptor- positive breast cancers, triple-negative tu‐
mors lack an established therapeutic target and though initially responsive to many stand‐
ard treatment regimens, progression and recurrence can be rapid and refractory to
alternative approaches. Loss or inactivation of breast cancer type 1 (BRCA1) leads to defects
in certain DNA repair pathways. Most BRCA1 mutant breast cancers lack ER, PgR, and
HER2 expression, and this association has raised the question of defective BRCA1 function
in sporadic (non-familial) TNBC (Sorlie et al., 2003). This led to the hypothesis that triple-
negative tumors may be more sensitive to DNA damaging agents, such as platinums. A ret‐
rospective analyses of patients with triple-negative breast cancer who received taxane/
platinum-based primary chemotherapy demonstrated an overall response of 39% (Uhm et
al., 2009), while studies of platinum monotherapy or combinations in the neoadjuvant set‐
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ting have produced pCR rates of 22%-50% (Garber et al., 2006; Chang et al., 2008; Byrski et
al., 2009; Schott et al., 2011).
3. Molecular profiling in prognosis and patient selection for neoadjuvant
systemic therapy
Gene expression profiling with the use of DNA microarrays has added valuable information
to our understanding of breast cancer biology. In the seminal work of Perou et al. (2011) the
ability to interrogate thousands of genes at the same time was translated into a "molecular
portrait" of each tumor sample studied, and the concomitant analysis of the individual mo‐
lecular portraits of breast cancer tumor samples made the definition of molecular subtypes
of breast cancer possible (Perou et al., 2011). In order to analyze this large quantity of infor‐
mation (thousands of genes per sample evaluated), a hierarchical clustering method was
used to group genes according to similar patterns of expression. The proposed molecular
classification of breast cancer was divided into five classes: luminal-A, luminal-B, basal-like,
HER2-positive and normal-like tumors (Sotiriou et al., 2003; Sorlie et al., 2003). Subsequent‐
ly, the correlation between molecular subtypes and clinical data have shown a significant
difference in overall survival between the subtypes.
Despite this progress, the clinical applicability of molecular classification is limited by the
tight correlation between the molecular subtypes and currently available immunohisto‐
chemical markers (ER, PR, HER2, Ki67) (Sotiriou & Pusztai, 2009). For example, the molecu‐
lar subtype HER2-positive is clinically detected by IHC or fluorescent in situ hybridization
(FISH) according to published guidelines (Sauter et al., 2009). Although a good correlation
has been established between the molecular subtype HER2 and clinically assessed HER2-
positive breast cancer, the opposite is not true, because 30% of HER2-positive breast cancers
are molecularly characterized as luminal-B (Cheang et al., 2009). Luminal-A and luminal-B
molecular subtypes are, by definition, hormone receptor positive tumors, but the distinction
between these two subtypes is controversial.
One of the proposed clinical definitions characterizes luminal-A and luminal-B tumors us‐
ing hormone receptor status, HER2 status and the Ki67 index (percentage of Ki67-positive
nuclei by IHC). Luminal-A is defined as being ER- and/or PR-positive, HER2-negative and
Ki67-low (Ki67 index < 14%). Luminal-B is defined as ER- and/or PR- positive, HER2- nega‐
tive and Ki67-high (Ki67 index > 14%). Another luminal-B subtype has also been proposed,
namely luminal HER2 enriched, with tumors being ER- and/or PR- positive, HER2-positive
and Ki67-high (ki67 index > 14%) (Perou, 2011).
Study Jinno et al (2011) was to evaluate the clinical utility of breast cancer intrinsic subtypes
in the prediction of pathological complete response (pCR) in a cohort of breast cancer pa‐
tients receiving neoadjuvant chemotherapy.
Patients with stage II/III breast cancer received 4 cycles of chemotherapy XT (capecitabine
1650mg/m2 on days 1-14 and docetaxel 60mg/m on day 8 every 3 weeks), followed by 4 cy‐
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cles of FEC (fluorouracil 500 mg/m2, epirubicin 90mg/m2, cyclophosphamide 500mg/m2).
Immunohistochemical (IHC) analysis of ER, PgR, HER2. EGFR, cito-ceratine 5/6. and Ki67
was performed in core needle biopsy samples at baseline. Tumors were classified as luminal
A (ER+ and/or PgR+, and Ki67<20%), Luminal В (ER+ and PgR+, and Ki67 > 20%). Luminal-
HER2 (ER+ and/or PgR+, and HER2+), HER2-enriched (ER- PgR-, and HER2+), or triple-neg‐
ative (ER-, PgR-, and HER2-). Triple-negative tumors with and without EGFR+ and/or cito-
ceratine 5/6+ were further classified as basal-like and non-basal-like TN (NBTN),
respectively. Pathologic complete response (pCR) was defined as no microscopic evidence
of residual viable tumor cells, invasive or noninvasive, in all resected specimens of the
breast. Twenty-six (31.3%) patients were classified as luminal A, 12 (14.5%) were luminal B,
15 (18.1%) were luminal-HER2, 9 (10.8%) were HER2, 10 (12.0%) were basal like, and 11
(13.3%) were NBTN. The overall response rate was 90.4%, including a complete response in
30 patients and a partial response in 45 patients. The overall pCR rate was 15.5% (12/83). The
highest pCR rate (40.0%) was observed in patients with basal- like tumors. In triple-negative
patients, basal-like patients showed significantly higher pCR rate than NBTN patients
(40.0% vs. 9.1%. p = 0.01). There were no cases with pCR in a cohort of luminal HER2 sub‐
type patients. A higher proportion of luminal В patients had 1 pCR than luminal A patients
(25.0% vs. 3.8%, p = 0.01). Data indicate that breast cancer subtypes are useful predictive bio‐
markers of pCR in breast cancer patients treated with neoadjuvant systemic chemotherapy.
According Sanpaolo et al (2011) study, breast cancer subtype seems a prognostic factor of
breast cancer specific survival and distant metastases rates, but not of local relapse rate. Pa‐
tient could be submitted to conservative surgery, if feasible, but considering the differenced
in survivals, patients with worse prognosis should receive more aggressive adjuvant treat‐
ment.
The goals of neoadjuvant therapy of breast cancer have significantly changed and evolved
since it was firstly applied to women with inoperable locally advanced and inflammatory
breast cancers in the early 1970’s. The extended indication to allow more breast conserving
surgery has widened the application of neoadjuvant treatments and provided evidence for
the association between favorable long term outcome and intermediate endpoints, like
pathologic complete response (pCR) after chemotherapy or decreased tumor proliferation
measured by Ki87 after endocrine therapy. A key question is whether pCR and Ki87 can
take the role of qualified and validated surrogate markers of drug efficacy, so that any dif‐
ference in survival between treatments disappeared after adjustment for the intermediate
endpoint. The recent improvements in understanding the molecular basis of breast cancer
heterogeneity has provided a new level of complexity but also an outstanding conceptual
framework for interpreting the role of' pCR as potential surrogate marker, and has made
clear that the biologic meaning of pCR is different in different molecular subtypes, and that
different molecular subtypes will require different intermediate surrogate endpoints. The
validation of the intermediate surrogates markers of efficacy would dramatically change the
landscape of development of new drugs for early breast cancer and do provide the rationale
for a comparative analysis of the intermediate endpoint instead of the final survival end‐
point. The feasibility of this major paradigm shift from large and lengthy adjuvant clinical
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trials to smaller and faster neoadjuvant trials is still the topic of discussion, and will be ad‐
dressed by regulators, biostatisticians, translational scientists and oncologists.
4. The surgical aspects of neoadjuvant therapy
4.1. The surgical management of patient who achieve a complete pathological response
after neoadjuvant therapy
Neoadjuvant systemic treatment (NST) is the standard treatment for locally advanced breast
cancer (BC) and a standard option for primary operable disease. This analysis aimed to
identify whether breast cancer patients receiving radiotherapy alone following a complete
clinical remission (cCR) to neoadjuvant chemotherapy had a worse outcome than those
treated with surgery.
We identified 8 studies of NST where breast cancer patients who achieved a cCR were eligi‐
ble for different types of local management: radiotherapy only or surgery. Primary out‐
comes were loco-regional recurrence, distant disease free survival (DDFS), overall survival
(OS) (Semiglazov, 2008; Clouth et al., 2007; Ring et al., 2004; Smith et al., 2002).
We performed subgroup mefa-anaIyses for the primary outcomes on the basis of local man‐
agement. Heterogeneity between the risk ratios for the same outcome between different
studies was assessed by use of the chi-square-based Q statistic.
Rates of pathologic complete response (pCR) range from 25% to 35,8% of patients who had a
cCR. If a cCR is considered as a "test" of pCR then the positive predictive value of cCR in all
eligible trials was low (range from 29.9% to 35%). For surgery and no surgery (radiotherapy
alone) groups respectively there were no significant differences in DDFS (summary risk ra‐
tio [RR]=0.94, 95% confidence interval [CI]=0.91- 1.07) or OS (RR= 1.00, 95% CI=0.99- 1.12).
But there was trend towards increased loco-regional recurrences for the radiotherapy only
group (difference in favor to surgery range from 11% to 20%; RR= 1.53, 95% CI= 1.11- 2.10;
P=O.02).
In patients achieving a cCR to neoadjuvant chemotherapy, radiotherapy alone achieve surviv‐
al rate as good as with surgery, but with higher local recurrence rate. A prospective random‐
ized trial addressing the need for surgery after cCR would seem reasonable in patient with
magnetic resonance or positron emission tomography-defined complete remissions.
4.2. Role of sentinel node biopsy after neoadjuvant systemic therapy
The surgical management of patients presenting early stage breast cancer (T1- T2) and clini‐
cally negative lymph nodes (NO) has long included both primary tumor resection and level
I/II axillary lymph node dissection (ALND). This last procedure has been largely substituted
by the sentinel lymph node biopsy (SLNB) which is nowadays recommended by most clini‐
cal guidelines for this subgroup of patients. Indeed, the well documented accuracy of SLNB
in predicting the axillary status implies that, in these patients, a negative sentinel lymph
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node (SLN) is considered sufficient to rule out metastases in other axillary nodes and to
avoid axillary dissection. Several randomized clinical trials have further indicated that
SLNB and ALND are comparable in terms of overall survival and incidence of nodal failure
(Canavese et al., 2011).
Over the years, neo-adjuvant chemotherapy (NAC) has become the preferred treatment for
patients with operable locally advanced breast cancer, in an attempt to reduce the tumor
mass and to favor breast-conservative surgery over mastectomy. In addition, NAC has been
shown to down-stage the axillary status in some 30-40% of the patients treated. Based on the
SLNB validation studies mentioned above, it would be reasonably legitimate to introduce
the SLNB procedure also in the context of NAC. However, one frequent adverse effect of
NAC is the anatomical alteration of the lymphatic drainage, with lymphatic vessels disrupt‐
ed by tumor, inflammation or fibrosis, or blocked by necrotic and/or apoptotic cells; in addi‐
tion, NAC could induce a non-uniform tumor regression in the axillary nodes, being most
effective in some nodes but not in others.
These events could prevent a proper diffusion of the scintigraphic tracer during lymphatic
mapping, in the one hand, and contribute to a reduction in the rate of successful SLN identi‐
fication and, more importantly, an increase in the rate of false-negative SLN. Therefore, the
demonstration of the feasibility and accuracy of SLNB after NAC is of major interest since in
the future responders to NAC who would be down-staged to a negative nodal status (NO)
could be spared a complete axillary dissection and the immediate sequelae of axillary sur‐
gery. Two large NSABP trials have incorporated SLN biopsy either before chemotherapy
(B-32, 5536 patients) or after NAC (B-27, 428 patients) and report comparable mapping suc‐
cess (97% vs 89%) and false negative rates (9.8% vs 9.3%) for combined blue dye and radio‐
activity.
There is a current SNB trial looking at SNB before and after neoadjuvant systemic therapy in
Germany called SENTINA(Kuehn et al., 2009). This is a four arm study. Patients who are
clinically node-negative have SLNB prior to NAC. Those who are SLNB negative at diagno‐
sis have no further axillary procedure after NAC whereas those who are SLNB
Positive proceed after NAC to a further SLNB and axillary dissection. Clinical node-positive
patients have primary systemic therapy and those that are clinically node-negative go on to
have SLNB and axillary lymph node dissection, whereas those who are clinically node-posi‐
tive undergo axillary lymph node dissection alone. Over 600 patients have been enrolled to
date. The study design is somewhat complex but will add to the body of knowledge on the
value of ALNB after NAC
Dixon and Cody (2010) recommend that all patients at diagnosis have axillary ultrasound
and that any suspicious nodes should be submitted to fine needle aspiration cytology or
core biopsy. Those who appear to be node-negative on the basis of clinical exam, imaging,
and needle biopsy should have SLN biopsy post-NAC, at the same time as their breast sur‐
gery, to assess the extent of any remaining disease. Those with proven axillary node meta‐
stases at diagnosis should also be considered for SLN biopsy post-NAC. For patients with
triple-negative or HER2-positive disease there is a more than 50% chance that all involved
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nodes will be sterilized by NAC +/- trastuzumab. This contrasts to patients with ER-positive
disease who have an approximate 4% rate of axillary node sterilization. These data can be
used to inform patients at the outset of treatment as to the possible surgical options for the
axilla after NAC. For patients with involved nodes at diagnosis who have a complete clinical
and imaging response in the axilla, SLN biopsy is reasonable post-NAC and ALND can be
avoided if the SLN is negative. For the remaining patients whose nodes remain positive
post-NAC (less than half of those with triple-negative or HER2-positive cancers, and over
95% of those with ER-positive disease), ALND should remain the standard of care.
So intra-operative lymphatic mapping and SLNB are nowadays part of the standard man‐
agement of patients with early-stage breast cancer and clinically negative axillary nodes.
Based on the present results, this procedure is feasible and is an accurate predictor of the
axillary nodal status also when it is performed after NAC in patients with locally advanced
breast cancer. However, before introducing SLNB as a routine procedure in the context of
NAC, clinical trials will have to demonstrate that overall survival and disease-free survival
do not worsen when ALND is not performed in the subset of post-NAC SLN-negative pa‐
tients, thus leaving behind down-staged axillary nodes.
5. Conclusion
The neoadjuvant (preoperative, primary) use of cytotoxic, hormonal, and/or trastuzumab
therapy effectively reduces tumor burden in the breast and the axilla without compromising
survival. The risk of local recurrence is determined by the initial clinical stage and the patho‐
logic stage after neoadjuvant therapy. Neoadjuvant therapy is indicated in patients with in‐
operable tumors or if BCT is desired by patients with large tumors otherwise requiring
mastectomy. Patients with multicentric tumors generally will not become candidates for
BCT with this approach. Initial multidisciplinary evaluation is important. The tumor site
should be marked before treatment (eg, by clipping) to allow tumor localization at surgery.
Multiple imaging studies are not needed during treatment unless there is concern about dis‐
ease progression. Surgery is necessary in all patients, even those with a complete clinical re‐
sponse. Any residual palpable or imaging-detected lesions should be removed, but the
entire initial rumor volume does not need to be resected in tumors showing a reduction in
size. The optimal timing of sentinel lymph node biopsy in relation to neoadjuvant systemic
therapy in patients with a clinically lymph node-negative axilla is uncertain at this time, and
further study is required. The identification rate of the sentinel lymph node appears to be
lower after neoadjuvant therapy, but some patients may avoid axillary lymph node dissec‐
tion because of downstaging. Ultrasonography of the axilla in clinically lymph node-nega‐
tive patients is useful in identifying pathologically lymph node-positive patients at
presentation. In some cases, knowledge of the pretreatment lymph nodal status is useful for
radiation planning. In patients with lymph node-positive disease at presentation who be‐
come clinically lymph node-negative after treatment, axillary dissection is recommended be‐
cause of the high false-negative rate of SNB in this circumstance. Postoperative radiation
therapy is recommended for all patients treated with breast-conserving surgery and for all
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patients with initially lymph node-positive disease or with locally advanced disease treated
with mastectomy.
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